Forward-Looking Information

This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations.

In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.

This presentation also contains certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com.
Our Strategic Foundation

Best of BIOTECH

Best of PHARMA

Diversified Specialty BioPharma

INNOVATE • INTEGRATE • IMPROVE

People helping patients in their fight against serious disease

Not For Product Promotional Use
Our R&D Focus

DISEASE AREA FOCUS

- Immuno-Oncology
- Immunoscience
- Cardiovascular
- Genetically Defined Diseases
- Oncology
- Virology
- Fibrotic Diseases

MODALITIES

- Small Molecules
- Biologics
- Gene Therapy
- Millamolecules
- Antibody Drug Conjugates
BMS Specialty Development Strategy

- High Severity
- Enduring Unmet Need
- Potentially Transformational Treatment Effect
Building a Diverse Specialty Portfolio

**Virology**
Functional cure – HIV and chronic HBV
ImmunoVirology

**Cardiovascular**
Heart Failure
Arrhythmias
Atherosclerosis
Thrombosis

**Immunoscience**
Remission in RA, IBD, Lupus
New diseases based upon MOA

**Fibrotic Diseases**
Lung
Kidney
Liver

**Genetically Defined Diseases**
Monogenic diseases
Sentinel populations
Specialty Development Portfolio

**Virology**
- **REYATAZ**
- **DAKLINZA**
- **SUNVEPRA**
  - Beclabuvir (NS5B Non Nuc)
  - HIV Attachment Inhibitor
  - HIV Maturation Inhibitor
  - Anti-PD-L1

**Immunoscience**
- **ORENCIA**
  - Lulizumab (Anti-CD28)
  - Anti-CD40
  - Anti-CD40L
  - BTK Inhibitor
  - S1P1 Agonist

**Fibrotic Diseases**
- **ELIQUISS**
  - LPA1 Antagonist
  - Galectin-3 Inhibitor
  - IKur Inhibitor
  - Factor Xla Inhibitor
  - PAR4 Antagonist

**Cardiovascular**
- **ELIQUISS**
  - Anti-Myostatin
  - Anti-eTau

**Genetically Defined Diseases**
- **Anti-eTau**

As of May 1, 2015
Enhancing Our Pipeline through Business Development

Trademarks are the property of their respective owners

Not For Product Promotional Use